Mark Wildgust, The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Looking forward to ASCO25 starting next week and right after it EHA25.
Amazing data and opportunities to connect and come together as a community with our shared goals of Getting In Front of Cancer.”
Mark Wildgust expressed enthusiasm for the upcoming ASCO25 and EHA25 meetings, emphasizing data sharing and collaboration in the oncology community.
More posts featuring Mark Wildgust.